Compare Stocks: HURA, ENTX, PRTA, and KYTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$3.00 +1.7%	$2.55	$0.91 ▼ $4.20	$512.81M	1.38	346,373 shs	603,193 shs
HURA TuHURA Biosciences	$2.14 +1.9%	$2.22	$0.41 ▼ $3.43	$133.83M	-0.02	265,570 shs	367,762 shs
KYTX Kyverna Therapeutics	$8.25 -1.2%	$8.20	$3.60 ▼ $13.67	$516.39M	1.98	729,191 shs	500,780 shs
PRTA Prothena	$9.82 +2.3%	$9.07	$7.73 ▼ $11.80	$502.59M	-0.33	364,114 shs	383,926 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+1.69%	-0.99%	+6.76%	+154.24%	+47.78%
HURA TuHURA Biosciences	+1.90%	+1.42%	+2.39%	+8.63%	-17.69%
KYTX Kyverna Therapeutics	-1.20%	-1.43%	+7.98%	+10.44%	+121.77%
PRTA Prothena	+2.29%	+5.25%	+15.67%	+11.72%	+17.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$3.00 +1.7%	$2.55	$0.91 ▼ $4.20	$512.81M	1.38	346,373 shs	603,193 shs
HURA TuHURA Biosciences	$2.14 +1.9%	$2.22	$0.41 ▼ $3.43	$133.83M	-0.02	265,570 shs	367,762 shs
KYTX Kyverna Therapeutics	$8.25 -1.2%	$8.20	$3.60 ▼ $13.67	$516.39M	1.98	729,191 shs	500,780 shs
PRTA Prothena	$9.82 +2.3%	$9.07	$7.73 ▼ $11.80	$502.59M	-0.33	364,114 shs	383,926 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+1.69%	-0.99%	+6.76%	+154.24%	+47.78%
HURA TuHURA Biosciences	+1.90%	+1.42%	+2.39%	+8.63%	-17.69%
KYTX Kyverna Therapeutics	-1.20%	-1.43%	+7.98%	+10.44%	+121.77%
PRTA Prothena	+2.29%	+5.25%	+15.67%	+11.72%	+17.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	2.00	Hold	$9.00	200.00% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	320.56% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	263.64% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	150.22% Upside

Current Analyst Ratings Breakdown

Latest HURA, ENTX, PRTA, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	PRTA Prothena	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/23/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.04 per share	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.29 per share	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$2.68 per share	N/A
PRTA Prothena	$9.68M	53.11	N/A	N/A	$5.48 per share	1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.38	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)

Latest HURA, ENTX, PRTA, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	8.98	8.98
HURA TuHURA Biosciences	0.20	0.18	0.18
KYTX Kyverna Therapeutics	0.15	9.06	9.06
PRTA Prothena	N/A	25.05	25.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
HURA TuHURA Biosciences	0.62%
KYTX Kyverna Therapeutics	18.08%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.57%
HURA TuHURA Biosciences	6.06%
KYTX Kyverna Therapeutics	17.60%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	173.83 million	155.46 million	Optionable
HURA TuHURA Biosciences	N/A	63.73 million	59.87 million	N/A
KYTX Kyverna Therapeutics	96	61.84 million	50.96 million	Optionable
PRTA Prothena	130	52.35 million	46.91 million	Optionable

HURA, ENTX, PRTA, and KYTX Headlines

Recent News About These Companies

Prothena (NASDAQ:PRTA) Major Shareholder Purchases 27,000 Shares of Stock

September 4 at 6:52 AM | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases $255,690.00 in Stock

September 3 at 7:21 PM | marketbeat.com

Prothena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 24, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares

August 22, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock

August 21, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?

August 19, 2026 | marketbeat.com

KMDA or PRTA: Which Is the Better Value Stock Right Now?

August 14, 2026 | zacks.com

HC Wainwright Issues Positive Estimate for Prothena Earnings

August 11, 2026 | marketbeat.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 8, 2026 | theglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 7, 2026 | zacks.com

Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2026 | marketbeat.com

Prothena: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026 | businesswire.com

Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA

August 6, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Insider Sells $64,897.14 in Stock

July 31, 2026 | insidertrades.com

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026 | finance.yahoo.com

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

July 9, 2026 | zacks.com

Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

June 26, 2026 | finance.yahoo.com

SRPT or PRTA: Which Is the Better Value Stock Right Now?

June 24, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, ENTX, PRTA, and KYTX Company Descriptions

Entera Bio NASDAQ:ENTX

$3.00 +0.05 (+1.69%)

As of 09/4/2026 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

TuHURA Biosciences NASDAQ:HURA

$2.14 +0.04 (+1.90%)

As of 09/4/2026 04:00 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Kyverna Therapeutics NASDAQ:KYTX

$8.25 -0.10 (-1.20%)

As of 09/4/2026 04:00 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Prothena NASDAQ:PRTA

$9.82 +0.22 (+2.29%)

As of 09/4/2026 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ENTX, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ENTX, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ENTX, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, ENTX, PRTA, and KYTX Company Descriptions

Entera Bio NASDAQ:ENTX

TuHURA Biosciences NASDAQ:HURA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ENTX, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ENTX, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ENTX, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, ENTX, PRTA, and KYTX Company Descriptions

Entera Bio NASDAQ:ENTX

TuHURA Biosciences NASDAQ:HURA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools